Point72 Asia (Singapore) Pte. Ltd. Editas Medicine, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $379 Billion
- Q4 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 36,343 shares of EDIT stock, worth $74,866. This represents 0.01% of its overall portfolio holdings.
Number of Shares
36,343
Previous 93,789
61.25%
Holding current value
$74,866
Previous $320 Million
85.57%
% of portfolio
0.01%
Previous 0.06%
Shares
3 transactions
Others Institutions Holding EDIT
# of Institutions
225Shares Held
54.2MCall Options Held
412KPut Options Held
355K-
Black Rock Inc. New York, NY7.78MShares$16 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.82MShares$14.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.75MShares$5.66 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.16MShares$4.45 Million0.0% of portfolio
-
State Street Corp Boston, MA1.87MShares$3.86 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $142M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...